Loading
When a public company announces a trial failure, it should be required to give the actual numbers, as it must for a success.
Securities regulators require disclosure of material events, and trial failures are material. Yet failure announcements typically omit effect sizes, confidence intervals and safety, which are routinely disclosed for successes. A securities-regulation rule that material trial announcements include a standard minimum data set (primary endpoint estimate with interval, key secondaries, serious adverse events) would put the numbers in the public record within days rather than years.
Shares Public post-mortem reports when a cancer drug programme is stopped, Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Public post-mortem reports when a cancer drug programme is stopped, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Incentives reward me-too drugs and marginal gains.